Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 6/20 | 0.59 |
| ▸ | ANO1 | Q5XXA6 | 9/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30285854 | 1.00 | P2RX4 (0.59) | P2RX4ANO1ROCK2SMN1; SMN2ACKR3 | |
| SCHEMBL29005403 | 0.96 | P2RX4 (0.65) | P2RX4ANO1SMN1; SMN2 | |
| SCHEMBL24173483 | 0.94 | P2RX4 (0.58) | P2RX4ANO1ROCK2ACKR3 | |
| SCHEMBL26186501 | 0.93 | P2RX4 (0.68) | P2RX4ANO1 | |
| SCHEMBL30285601 | 0.93 | P2RX4 (0.68) | P2RX4ANO1 | |
| SCHEMBL30285786 | 0.93 | P2RX4 (0.60) | P2RX4ANO1ROCK2 | |
| SCHEMBL26186489 | 0.93 | P2RX4 (0.60) | P2RX4ANO1ROCK2 | |
| SCHEMBL30285732 | 0.92 | P2RX4 (0.56) | P2RX4ANO1ROCK2 | |
| SCHEMBL26186524 | 0.92 | P2RX4 (0.56) | P2RX4ANO1ROCK2 | |
| SCHEMBL25373470 | 0.91 | P2RX4 (0.60) | P2RX4ANO1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230270729-A1 | USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTIAN OCULAR DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-31 | — | — | US | claimed |
| US-20230257351-A1 | SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-17 | — | — | US | claimed |
| EP-4171744-A1 | USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTAIN OCULAR DISORDERS | Bayer Aktiengesellschaft (DE) | 2023-05-03 | — | — | EP | claimed |
| EP-4172146-A1 | SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY | Bayer Aktiengesellschaft (DE) | 2023-05-03 | — | — | EP | claimed |
| WO-2022002859-A1 | SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY | BAYER AKTIENGESELLSCHAFT (DE) | 2022-01-06 | — | — | WO | claimed |
| WO-2022002860-A1 | USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTAIN OCULAR DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-01-06 | — | — | WO | claimed |
| US-20230270729-A1 | USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTIAN OCULAR DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-31 | — | — | US | disclosed |
| US-20230270729-A1 | USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTIAN OCULAR DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-31 | — | — | US | disclosed |
| US-20230270729-A1 | USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTIAN OCULAR DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-31 | — | — | US | disclosed |
| US-20230257351-A1 | SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-17 | — | — | US | disclosed |
| US-20230257351-A1 | SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-17 | — | — | US | disclosed |
| US-20230257351-A1 | SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-17 | — | — | US | disclosed |
| CN-115996911-A | Substituted N-phenylacetamides having P2X4 receptor antagonistic activity | 拜耳公司 | 2023-04-21 | — | — | CN | disclosed |
| CN-115989218-A | Use of N-phenylacetamides having P2X4 receptor antagonistic activity for the treatment of certain eye diseases | 拜耳公司 | 2023-04-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257351-A1 | SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY | P2RX2, P2RX5, P2RX3 | P2RX4 4/4885ANO1 964/4885ROCK2 4776/4885 |
| US-20230270729-A1 | USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTIAN OCULAR DISORDERS | P2RX2, P2RX4, P2RX5 | P2RX4 2/4885ANO1 3464/4885ROCK2 3999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.